AST 487 is primarily used in research settings as a selective inhibitor of receptor tyrosine kinases, particularly targeting the RET kinase pathway. It has been investigated for its potential in oncology, especially in cancers driven by RET gene rearrangements or mutations, such as certain thyroid and lung cancers. By blocking RET signaling, AST 487 helps suppress tumor cell proliferation and induce apoptosis in preclinical models. It is also employed as a tool compound to study kinase inhibition mechanisms and signaling pathways in cellular and animal studies. Its application remains largely confined to laboratory research and drug development rather than clinical use.